bluuebunny/crossref_metadata_2025_split huggingface dataset:
Electromagnetic properties of the $$\Sigma _{c}(2800)^+$$ and $$\Lambda _c(2940)^+$$ states via light-cone QCD
Authors: Ozdem Ulaş 
Published: November 2023

AbstractThe $$\Sigma _{c}(2800)^+$$

Σ
c

(
2800
)

+

and $$\Lambda _c(2940)^+$$

Λ
c

(
2940
)

+

states are among the most interesting and intriguing particles whose internal structures have not yet been elucidated. Inspired by this, the magnetic dipole moments of the $$\Sigma _{c}(2800)^+$$

Σ
c

(
2800
)

+

and $$\Lambda _c(2940)^+$$

Λ
c

(
2940
)

+

states with quantum numbers $$J^P = \frac{1}{2}^-$$

J
P

=

1
2

-

and $$J^P = \frac{3}{2}^-$$

J
P

=

3
2

-

, respectively, are analyzed in the framework of QCD light-cone sum rules, assuming that they have a molecule composed of a nucleon and a $$D^{(*)}$$

D

(

∗
)

meson. The magnetic dipole moments are obtained as $$\mu _{\Sigma _c^{+}}=0.26 \pm 0.05~\mu _N$$

μ

Σ
c
+

=
0.26
±
0.05

μ
N

and $$\mu _{\Lambda _c^{+}}=-0.31 \pm 0.04~\mu _N$$

μ

Λ
c
+

=
-
0.31
±
0.04

μ
N

. The magnetic dipole moment is the leading-order response of a bound system to a weak external magnetic field. It therefore offers an excellent platform to explore the inner organization of hadrons governed by the quark-gluon dynamics of QCD. Comparison of the findings of this analysis with future experimental results on the magnetic dipole moments of the $$\Sigma _{c}(2800)^+$$

Σ
c

(
2800
)

+

and $$\Lambda _c(2940)^+$$

Λ
c

(
2940
)

+

states may shed light on the nature and internal organization of these states. The electric quadrupole and magnetic octupole moments of the $$\Lambda _c(2940)^+$$

Λ
c

(
2940
)

+

states have also been calculated, and these values are determined to be $${\mathcal {Q}}_{\Lambda _c^+} = (0.65 \pm 0.25) \times 10^{-3}$$

Q

Λ
c
+

=

(
0.65
±
0.25
)

×

10

-
3

fm$$^2$$

2

and $$ {\mathcal {O}}_{\Lambda _c^+} = -(0.38 \pm 0.10) \times 10^{-3}$$

O

Λ
c
+

=
-

(
0.38
±
0.10
)

×

10

-
3

fm$$^3$$

3

, respectively. The values of the electric quadrupole and magnetic octupole moments show a non-spherical charge distribution. We hope that our estimates of the electromagnetic properties of the $$\Sigma _{c}(2800)^+$$

Σ
c

(
2800
)

+

and $$\Lambda _c(2940)^+$$

Λ
c

(
2940
)

+

states, together with the results of other theoretical studies of the spectroscopic parameters of these states, will be useful for their search in future experiments and will help us to define the exact internal structures of these states.
Nursing Session
Authors: BRADBURY Linda 
Published: November 2023

The management of pain in inflammatory arthritis can be complicated. Its important to differentiate between different types of pain, explain these to the patient and treat accordingly. Pain can be due to inflammatory disease eg rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis; tissue damage eg osteoarthritis; nerve pain eg shingles, carpal tunnel; or due to increased sensitivity of the pain system eg fibromyalgia. Patients may have a combination of two or more of these which can be challenging not only for the patient but also the clinician. Understanding the signs and symptoms of each is vital for the rheumatology nurse to be able to fully assess and evaluate care. Individualised care is important as everyone’s perception of pain is different. Factors such as sleep, physical health, diet and mental health can also play a role and so a holistic approach is essential. Management of the rheumatology patient involves a combination of pharmacological therapies but, probably more importantly from the rheumatology nurse point of view, non-pharmacological approaches. Of course, the diagnosis will determine the pharmacological treatments but can more be done? With a focus on pain, this presentation will follow a patient who is attending the rheumatology clinic with a diagnosis of inflammatory arthritis but their journey is not as simple as it sounds.
Lunch Symposium
Authors: STEVENS Wendy 
Published: November 2023

Pulmonary arterial hypertension (PAH), defined as the presence of artery pulmonary artery pressure > 20 mmHg, pulmonary artery wedge pressure [Formula: see text]15 mmHg, and pulmonary vascular resistance (PVR) > 2Wood units based on expert consensus, is characterized by a progressive and sustained increase in PVR, which may lead to right heart failure and death. PAH is a well-known complication of connective tissue diseases (CTDs), such as systemic sclerosis, systemic lupus erythematosus, Sjögren’s syndrome, and other autoimmune conditions. In the past few years, tremendous progress in the understanding of PAH pathogenesis has been made, with various novel diagnostic and screening methods for the early detection of CTD-PAH proposed worldwide. This symposium would highlight the most updated 2022 ESC/ERS guideline in the disease management of PAH, including latest haemodynmaic definitions of PAH, new risk stratification approach at reassessment and updated PAH treatment recommendations. In addition to the guideline update, important discussion would cover the important diagnostic, and screening algorithm for early detection of CTD-PAH and clinical experiences in managing difficult CTD-PAH cases.
Symposium 4
Authors: SMITH Vanessa 
Published: November 2023

Interstitial lung disease (ILD) is a fibrotic disease of the lung parenchyma. It can occur in different connective tissue diseases, including rheumatoid arthritis (RA). Smoking, male gender and longstanding RA are possible risk factors for developing ILD 1 . Being a common extra-articular manifestation of RA, it can contribute to decreased quality of life, chronic disability, high utilization of healthcare resources, and may also lead to substantial morbidity and mortality for affected patients1. Hence, early identification and management is of paramount importance to improve patient outcomes. Clinical presentation, chest X-ray, pulmonary function testing and high-resolution computed tomography are common tools for investigation and they also allows assessment of subtype and disease extent 2 . The histopathologic and radiographic features of RA-ILD are heterogeneous. The most frequent patterns of RA-ILD are usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). Distinguishing the patterns is useful in predicting prognosis and would also affect subsequent management approach 2 . Traditionally treatment initiated for RA-ILD was generally empirical. Corticosteroids were often used as first-line agents and immunosuppressants maybe added2. However, these treatments are not specific and mainly target inflammation instead of fibrosis. With the advance in medicine, antifibrotic is now indicated for treating fibrosing ILD with progressive phenotype. FVC decline can be slowed in patients with connective tissue disease associated progressive ILD 3 . In this lecture, Prof. Vanessa Smith will share the current knowledge and evidence in RA-ILD. The approach on identifying and screening ILD in RA patients would be presented. The management strategy and options would also be reviewed.
Symposium 4
Authors: CHAN Shirley 
Published: November 2023

Extra-articular manifestations are common in Rheumatoid-arthritis (RA), involving the skin, eyes, heart, and lung, causing significant comorbidities. In particular, clinically significant rheumatoid arthritis-associated interstitial lung disease (RA-ILD) has a prevalence of about 10%-19% among RA patients. However, the exact prevalence of ILD in RA patients is not well known and there is also a lack of local data in Hong Kong. Early screening and identification of ILD in RA patients is important for improving patient outcomes. Currently, there is no established algorithm for screening in asymptomatic patients with RA. High resolution computed tomography (HRCT) is a standard assessment in ILD diagnosis but is associated with high cost. Pulmonary function test and lung ultrasound might also be useful in identifying ILD. Besides, multiple clinical risk factors and novel biomarkers have been explored for early identification of RA-ILD. To evaluate the usefulness of these predictors and to evaluate the burden of interstitial lung disease (ILD) among patients with RA, a local study (RAISE, Rheumatoid Arthritis-associated ILD: Screening and Evaluation in high-risk patients) was designed in Hong Kong to assess the prevalence of RA-ILD among RA patients with high risk, and to identify potential clinical and biochemical markers associated with the condition. In this session, Dr. Shirley Chan will share the protocol of the RAISE study and the screening approach. The interim results will also be analyzed and presented.
Symposium 10: Spotting EGPA from Asthma Populations and How Co-Care Works Between Rheumatology and Respiratory Physicians: A Case Sharing
Authors: KUO Ping-Hung 
Published: November 2023

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic vasculitis characterized by asthma, eosinophilia, and vasculitic organ involvement. This rare disease poses diagnostic challenges within the domain of severe asthma. Recognizing EGPA within the asthmatic cohort is therefore crucial for appropriate management and improved patient outcomes. Moreover, effective collaboration between rheumatologists and respiratory physicians is vital for the comprehensive care of EGPA patients. This scientific lecture aims to discuss the identification of EGPA in individuals with asthma and highlight the importance of co-care between rheumatology and respiratory medicine. This lecture will begin by providing an overview of EGPA, its clinical manifestations, and the challenges associated with differentiating it from severe asthma. The crucial identification of distinctive clinical features, such as refractory asthma, peripheral eosinophilia, and systemic symptoms, which serve as beacons for the presence of EGPA, will be discussed. Diagnostic tools encompassing imaging, laboratory tests, and biopsy techniques are explored, focusing on their utility in distinguishing EGPA from asthma. Concomitantly, the lecture will then shift its focus to the collaborative efforts required from rheumatologists and respiratory physicians in managing EGPA patients. The complementary roles of both specialties in achieving optimal patient outcomes will be discussed. Rheumatologists play a crucial role in the diagnosis and treatment of systemic vasculitis, including EGPA, while respiratory physicians provide expertise in managing asthma and respiratory complications. The case will highlight the importance of open communication, shared decision-making, and coordinated treatment plans to ensure comprehensive care for EGPA patients, addressing both their rheumatologic and respiratory needs. Real-life case will be shared to illustrate successful co-management models between rheumatology and respiratory medicine. These examples will underscore the benefits of a multidisciplinary approach, including improved disease management, reduced treatment-related complications, and enhanced patient satisfaction. In conclusion, identifying EGPA within the asthma population is crucial for appropriate management, and effective collaboration between rheumatology and respiratory physicians is essential for comprehensive care. This scientific lecture aims to provide insights into spotting EGPA among asthma patients and emphasize the significance of co-care between these specialties, ultimately improving patient outcomes and quality of life.
Abstract 9 — Sphingosine-1-Phosphate Phosphatase Expression in SLE when Compared with Other Connective Tissue Disorders: A Bioinformatic Analysis
Authors: Tomo Sojit , Gopalakrishnan Maya , Banerjee Mithu 
Published: November 2023

Background Sphingolipids are major components of the plasma membrane which are acted upon by various enzymes to generate signaling molecules. The metabolites of the sphingolipid pathway have been identified to play a major regulatory role in various cellular processes. Sphingosine-1-phosphate (S1P) is one of the major intermediary molecules of the sphingolipid pathway. Sphingosine-1-phosphate, formed in the cell can be dephosphorylated by S1P-phosphatase (SGPP1 and SGPP2), which is a reversible process. Dysregulation of the sphingolipid pathway has been associated with multiple connective tissue disorders. The current study aimed to assess and compare differential gene expressions of SGPP1 and SGPP2 in patients with SLE when compared with other connective tissue diseases. Methods The current bioinformatics analytic study was conducted using publicly available datasets. Existing datasets from the ADEx: Autoimmune Diseases Explorer Database pertaining to connective tissue disorders were used to explore differentially expressed genes involved in sphingolipid pathways in patients with SLE when compared with other CTD. The differential expression of SGPP1 and SGPP2 genes of the sphingolipid pathway will be identified from datasets. Results The differential expression of SGPP1 and SGPP2 has been identified from the ADEx database. A total of 51 datasets, comprising 17 datasets of RA, 9 datasets of Sjogren Syndrome, 20 datasets of SLE, and 5 datasets of Systemic Sclerosis were used for analysis. An FDR filter of 0.01 was used during the analysis. On analysis, we observed an increased expression of SGPP1 in 2 RA datasets, 1 Sjogren Syndrome, and an increased expression of SGPP2 in 1 Systemic sclerosis dataset. However, in SLE datasets, the SGPP1 and SGPP2 were observed to have decreased expression. Conclusion Our study demonstrates a unique trend of SGPP1 and SGPP1 downregulated in SLE patients when compared with other CTD. This provides additional insight into the widely explored Sphingosine-1-phosphate-related dysregulation in SLE and will enable in devising of novel targeted therapy.
Abstract 11 — Development of a Novel Treg Activator KINE-101 for a New Treatment Option for Rheumatoid Arthritis
Authors: Kim Myun Soo , Kim Myun Soo , Park Sunyoung , Gu Chang Kyu 
Published: November 2023

Background KINE-101, a novel synthetic nonapeptide, is being developed for the treatment of rheumatoid arthritis with a distinctive mode of action. A study using a collagen-induced arthritis (CIA) mouse model showed that KINE-101 suppressed cartilage damage through inhibiting osteoclastogenesis. KINE-101 showed its therapeutic effects in suppressing auto-immune responses by activating Regulatory T cells (Tregs), a specialized subpopulation of T cells, in in-vivo studies using mouse models of RA. Following the in-vivo studies, the phase 1 clinical study for KINE-101 was conducted to assess the safety and tolerability in healthy subjects in the US. Methods Total 40 healthy subjects were enrolled to assign in 5 cohorts. Each cohort included 8 subjects composed of 6 active and 2 placebo treatment. The subjects of first 4 cohorts were administrated with 10, 30, 100, 300 mg of KINE-101 by intravenous (IV) infusion as single ascending doses (SAD), and the Cohort 5 subjects were subcutaneously (SC) injected with 96.8 mg of KINE-101. Results Except for 2 subjects in placebo group, all subjects completed the study. All the randomized subjects were included in the safety evaluation. No deaths, SAEs (Serious Adverse Events), or AEs (Adverse Events) leading to discontinuation were reported during the study periods. While total 9 TEAEs (Treatment-Emergent Adverse Events) were reported, all were assessed as mild. It included 3 headaches, 1 catheter site edema, 1 contusion and 1 nasal congestion in the treatment group, and 1 catheter site pain, 1 oral contusion and 1 COVID-19 infection in the placebo group. Oral contusion and COVID-19 occurred in the same subject, and all the other events were singular TEAEs reported in individual subjects. No injection site reactions were reported and no clinically significant changes in any laboratory values were noted. In terms of pharmacokinetic (PK) profile, KINE-101 was observed in the blood samples during and up to 5 minutes after infusion. Conclusion In the phase I clinical study, Treg activator KINE-101 demonstrated a favorable safety and tolerability profile. The most common AEs were headaches reported in 3 subjects, but all were mild and transient events. As typically seen in peptide drugs, KINE-101 has a short half-life. However, given that KINE-101 uses Treg as a proxy to exerts anti-inflammatory effects, its pharmacodynamic (PD) activity is likely to last longer. The next stage for KINE-101 will proceed to oral formulation and the Phase 2 clinical study in RA patients.
Abstract 12 — Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Study
Authors: Xiao Shiyu , Xie Wenhui 
Published: November 2023

Background Rheumatoid arthritis (RA) is a debilitating and financially burdensome disease because of frequent presence of comorbidities including metabolic and cardiovascular abnormalities. Growing evidence suggests a link between RA and nonalcoholic fatty liver disease (NAFLD). We aimed to determine the prevalence and explore the risk factors of developing NAFLD in RA population. Methods This population-based, cross-sectional study utilized data on US adults aged [Formula: see text]20 years old from the National Health and Nutrition Examination Survey (NHANES) 2017-2018, a representative sample of the general US population. Diagnosis of RA was derived from questionnaire data. NAFLD was defined by controlled attenuation parameter (CAP) scores of [Formula: see text]278 dB/m using vibration controlled transient elastography (VCTE) in the absence of other liver disease. Weighted multiple regression analysis was further performed to assess the independent risk factors. Results Of 2,848 people included in this study, 224 of them had self-reported RA. The prevalence of NAFLD in the overall sample was 41%, with a numerically higher prevalence in RA patients than those without arthritis (47% vs. 40%, p=0.30). Compared to those without NAFLD, RA patients with concomitant NAFLD had more prevalent metabolic comorbidities including obese (75% vs. 32%, p=0.006), central obesity (100% vs. 71%, p=0.008), diabetes (39% vs. 14%, p=0.003) and hyperlipidemia (88% vs. 76%, p=0.042). Regarding laboratory findings, RA patients with NAFLD exhibited higher levels of triglyceride (188 mg/dL vs. 131 mg/dL, p=0.010), fasting plasma glucose (131 mg/dL vs. 109 mg/dL, p=0.010) and HbA1c (5.77% vs. 6.41%, p=0.002). Meanwhile, elevated levels of liver enzymes (ALT: 29 U/L vs. 19 U/L, p=0.015; AST: 25 U/L vs. 19 U/L, p=0.007) and inflammatory indicator CRP (5.1 mg/dL vs. 3.4 mg/dL, p<0.001]) were more frequently reported in RA patients with NAFLD as compared with those without. Further, weighted multivariate logistic regression analysis showed that the presence of central obesity (adjusted OR=1.56 [95% CI 1.16-2.11], p=0.008) and diabetes (adjusted OR=1.28 [95% CI 1.07-1.54], p=0.014) were significantly associated with prevalent NAFLD in patients with RA. Conclusion In this population-based study, about one in two patients with RA had NAFLD, which is higher than its overall prevalence among general population. Central obesity and diabetes are predisposing factors for NAFLD in RA. Our results highlight the importance of active NAFLD screening in RA population, especially for high-risk subsets.
Abstract 13 — Comparison of Clinical and Serological Features in Juvenile and Adult-Onset Systemic Lupus Erythematosus
Authors: Salim Babur , Khan Anum , Gul Haris , Samreen Saba , Perveen Shahida 
Published: November 2023

Background Systemic lupus erythematosus (SLE) has varying clinical and serological features in juvenile and adult-onset disease groups, depending on the ethnicity. Objectives: To compare the disease characteristics of patients with adult-onset (ASLE) and juvenile-onset systemic lupus erythematosus (JSLE). Methods It is a cross-sectional study, carried out at Rheumatology department Fauji Foundation Hospital. 184 SLE patients were included. They were divided into adult (n=152) and juvenile (n=32) group. The clinical and serological features at the time of disease onset were compared between the two groups. Statistical analysis was done using chi square and t-test. Results The mean age was 36.22 ± 11.48 in adults and 19.94 ± 7.17 in the juvenile group (t = 7.71, p<0.001). The duration of disease was 46.05 ± 45.74 months(adult) and 62.43 ± 84.00 months (juvenile). There was no significant difference in disease activity, SLE disease activity index (SLEDAI) was 13 in adult lupus patients and 14.5 in the juvenile, t-value=1.1 and p-value=0.39. Sicca symptoms were significant in the ASLE (p=0.004). Neuropsychiatric manifestations (p=0.03), thrombocytopenia (p=0.048) and low complement levels (0.02) were significantly higher in JSLE. Serological profiles did not differ significantly in the two groups. Conclusion The features of SLE differ in adult and juvenile patients. Neurological involvement and thrombocytopenia were more prevalent in JSLE, whereas sicca symptoms were more frequently found in ASLE.
Abstract 16 — Are We Treating-to-Target on Spondyloarthritis (SpA)? A One-Year Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Authors: Cheng Isaac , So Ho , Yip Carson CY , Leung Ying Ying , Shin Kichul , Saeed Muhammad Ahmed , Chiowchanwisawakit Praveena , Hammoudeh Mohammed , Haroon Muhammad , Nallasivan Subramanian , Angkodjojo Stanley , Chung James Ho Yin , Kishimoto Mitsumasa , Wei James , Tam Lai Shan 
Published: November 2023

Background This analysis aimed to evaluate the extent of treat-to-target (T2T) achievement after 1-year intensive treatment in patients enrolled to the APLAR SpA registry. Methods Patients who fulfilled the CASPAR2006 for psoriatic arthritis (PsA), and 2009ASAS criteria for axial spondylitis (AxSpA) were recruited. Current analysis included the first 143 patients reaching the 1-year timepoint across 7 Asia-Pacific regions (Hong Kong, Singapore, Korea, India, Pakistan, Qatar and Thailand). Results 79 patients with PsA(age: 52±13 years, 43(55%) male, disease duration: 8.0±8.3 years) and 64 patients with AxSpA (age:41±16 years, 48(75%) male, disease duration: 4.8±7.2 years) were included. There were significant improvement in Disease Activity in Psoriatic Arthritis (DAPSA) (22.1±14.4 at baseline vs 11.5±10.0 at 1-year, p<0.001) while Ankylosing Spondylitis Disease Activity Score (ASDAS) remained stable. Other characteristics are listed in Table 1. Concerning the medication use, there was an increase in the number of patients receiving biologic/target synthetic disease-modifying drug (b/tsDMARDS, 29% at baseline to 61% at 1-year for PsA, and 52% at baseline to 64% at 1-year for AxSpA) (Fig. 1). Regarding T2T, 62% and 45% of PsA patient achieved DAPSA-low disease activity (DAPSA-LDA) and minimal disease activity (MDA) respectively, while 53% of patients with Axial SpA achieved ASDAS-LDA. The use of b/tsDMARDs was significantly higher in patient who achieved MDA when compared to those who did not (Fig. 1). The MDA/ASDAS-LDA achievement rate were comparable to that of the tight control arm of TICOPA cohort (41%) or TICOSPA study (60%) respectively. Treatment was escalated in 86% of visits when treatment target was not met. The reason for non-escalation of drug included: patients’choice (42%), mild symptoms only and physician decides to keep current regime (27%), adverse events (19%), no viable alternatives (8%) and others (4%). Conclusions Implementing the T2T strategy in patient with SpA was feasible in selected centres from the APLAR region, with similar target achievement rate compared to T2T studies conducted in Europe.